Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes 2012; 5: 2 5. 9. Takahashi O, Glasziou PP, Perera R et al. Lipid re-screening: what is the best measure and interval? Heart 2010; 96: 448 452. 10. Glasziou PP, Irwig L, Heritier S et al. Monitoring cholesterol levels: measurement error or true change? Ann Intern Med 2008; 148: 656 661. 11. Jafri H, Karas RH, Alsheikh-Ali AA. Meta-analysis: Statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010; 153: 800 808. 12. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486 2497. 13. Sandhu S, Wiebe N, Fried LF et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006; 17: 2006 2016. 14. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181 2192. 15. Lewington S, Whitlock G, Clarke R et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370: 1829 1839. 16. Chiang CK, Ho TI, Hsu SP et al. Low-density lipoprotein cholesterol: association with mortality and hospitalization in hemodialysis patients. Blood Purif 2005; 23: 134 140. 17. Coresh J, Longenecker JC, Miller III ER et al. Epidemiology of cardiovascular risk factors in chronic renal disease. 